Drug Trial News

RSS
Study assesses safety and efficacy of new treatment for pancreatic cancer

Study assesses safety and efficacy of new treatment for pancreatic cancer

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Study: Chemotherapy agent did not improve survival in patients with triple-negative breast cancer

Study: Chemotherapy agent did not improve survival in patients with triple-negative breast cancer

New study launched in Burkina Faso to test typhoid conjugate vaccine

New study launched in Burkina Faso to test typhoid conjugate vaccine

New ointment for treating brown recluse spider bites is tested on humans

New ointment for treating brown recluse spider bites is tested on humans

New antibody can reduce swelling attacks in patients with hereditary angioedema

New antibody can reduce swelling attacks in patients with hereditary angioedema

Botulinum toxin injections show promise to suppress postoperative atrial fibrillation

Botulinum toxin injections show promise to suppress postoperative atrial fibrillation

New drug shows promise for treating people with peanut allergy

New drug shows promise for treating people with peanut allergy

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

Oral antibiotic shows promise to cure uncomplicated gonorrhea

Oral antibiotic shows promise to cure uncomplicated gonorrhea

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Phase 2 STEMTRA trial using SB623 cells for treating traumatic brain injury meets primary endpoint

Phase 2 STEMTRA trial using SB623 cells for treating traumatic brain injury meets primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

AEGEA Medical begins PACE II clinical study in women who underwent endometrial ablation

AEGEA Medical begins PACE II clinical study in women who underwent endometrial ablation

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Investigational drug targeting the opioid system may help reduce symptoms of major depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.